International Petroleum Corporation Announces Confirmation of Corporate and Bond Credit Ratings
International Petroleum Corporation ("IPC" or the "Corporation") (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that international credit rating agencies S&P Global Ratings and Moody’s have reaffirmed IPC’s corporate and bond credit ratings. In respect of IPC’s corporate credit ratings, S&P Global Ratings has affirmed a credit rating of B with Stable outlook and Moody’s has affirmed a credit rating of B1 with Stable outlook. In respect of IPC’s outstanding USD 300 million 7.25% senior unsecured bonds with maturity in 2027 (ISIN NO 0012423476), S&P Global Ratings has affirmed a credit rating of B+ and Moody’s has affirmed a credit rating of B1.
International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO".
For further information, please contact:
VP Corporate Planning and Investor Relations
Tel: +41 22 595 10 50
Tel: +46 701 11 26 15
This press release contains statements and information which constitute "forward-looking statements" or "forward-looking information" (within the meaning of applicable securities legislation). Such statements and information (together, "forward-looking statements") relate to future events, including the Corporation's future performance, business prospects or opportunities. Actual results may differ materially from those expressed or implied by forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Forward-looking statements speak only as of the date of this press release, unless otherwise indicated. IPC does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws.
All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, forecasts, guidance, budgets, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", “forecast”, "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "budget" and similar expressions) are not statements of historical fact and may be "forward-looking statements".
The forward-looking statements are based on certain key expectations and assumptions made by IPC, including expectations and assumptions concerning: prevailing commodity prices and currency exchange rates; applicable royalty rates and tax laws; interest rates; future well production rates and reserve and contingent resource volumes; operating costs; the timing of receipt of regulatory approvals; the performance of existing wells; the success obtained in drilling new wells; anticipated timing and results of capital expenditures; the sufficiency of budgeted capital expenditures in carrying out planned activities; the timing, location and extent of future drilling operations; the successful completion of acquisitions and dispositions; the benefits of acquisitions; the state of the economy and the exploration and production business in the jurisdictions in which IPC operates and globally; the availability and cost of financing, labour and services; and the ability to market crude oil, natural gas and natural gas liquids successfully.
Although IPC believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because IPC can give no assurances that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to: the risks associated with the oil and gas industry in general such as operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of estimates and projections relating to reserves, resources, production, revenues, costs and expenses; health, safety and environmental risks; commodity price fluctuations; interest rate and exchange rate fluctuations; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of acquisitions; failure to complete or realize the anticipated benefits of acquisitions or dispositions; the ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals; and changes in legislation, including but not limited to tax laws, royalties and environmental regulations. Readers are cautioned that the foregoing list of factors is not exhaustive.
Additional information on these and other factors that could affect IPC, or its operations or financial results, are included in the management's discussion and analysis (MD&A) for the three and six months ended June 30, 2023 (See "Cautionary Statement Regarding Forward-Looking Information" “Risks and Uncertainties” and “Reserves and Resources Advisory” therein), the Corporation's Annual Information Form (AIF) for the year ended December 31, 2022 (See "Cautionary Statement Regarding Forward- Looking Information", "Reserves and Resources Advisory" and " Risk Factors" therein) and other reports on file with applicable securities regulatory authorities, including previous financial reports, management’s discussion and analysis and material change reports, which may be accessed through the SEDAR+ website (www.sedarplus.ca) or IPC's website (www.international-petroleum.com).
All dollar amounts in this press release are expressed in United States dollars, except where otherwise noted. References herein to USD mean United States dollars. References herein to CAD mean Canadian dollars.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Changes in Sampo Group Executive Committee and Board of Directors1.10.2023 11:05:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2023 at 12:05 pm Changes in Sampo Group Executive Committee and Board of Directors Following the completion of the partial demerger of Sampo plc, the Sampo Group Executive Committee (GEC) terms of Patrick Lapveteläinen, former Sampo Group CIO, and Petri Niemisvirta, CEO of Mandatum, have ended. Meanwhile, the new Sampo Group CIO Ville Talasmäki has joined the GEC today. Lapveteläinen and Niemisvirta have moved to Mandatum plc, a new company established in connection with the demerger to take up roles as Full-time Chair of the Board and CEO, respectively. Both Patrick Lapveteläinen and Petri Niemisvirta were members of Sampo GEC since 2001. Following the changes, the strength of the GEC has decreased from seven to six members. As previously communicated, the number of the members of the Board of Directors of Sampo has declined from ten to nine as Johanna Lamminen has left the Board as of today. Lamminen, who has been a member of the Sampo Board
Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki1.10.2023 11:00:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2022 at 12:00 pm NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki The completion of Sampo plc’s partial demerger has today been registered with the Finnish Trade Register and Mandatum has consequently been separated from Sampo Group, in accordance with the decision of Sampo’s Annual General Meeting on 17 May 2023. Nasdaq Helsinki has admitted the shares in Mandatum plc, the company incorporated in the demerger, to trading on the official list from 2 October 2023. - By separating Mandatum from Sampo, we have simplified the Group and created two entities that are well placed to create shareholder value. Sampo becomes a pure P&C insurance group, while Mandatum i
Redomiciliation to Bermuda completed30.9.2023 16:28:35 CEST | Press release
The Hague, September 30, 2023 - Aegon’s Extraordinary General Meeting of shareholders (EGM) today approved the cross-border conversion into a Bermuda Limited company. After the completion of the EGM, the change of Aegon’s legal seat to Bermuda has been effectuated, as a result of which the company became a Bermuda entity: Aegon Ltd. As of October 1, 2023, the Bermuda Monetary Authority will be Aegon’s group supervisor. Aegon shares will continue to be listed on Euronext Amsterdam (AGN) and NYSE (AEG). As at market open on October 2, 2023, trading will commence in Aegon Ltd. shares. The identifiers (such as the ISIN) of the Aegon shares will change: the Aegon Ltd. common shares will have the ISIN BMG0112X1056; andthe Aegon Ltd. common shares held in New York registry form will have the ISIN US0076CA1045 and the CUSIP 0076CA 104.1 More information on the redomiciliation, as well as the documentation relating to it, can be found here. Contacts Media relations Investor relations Richard Ma
Vow ASA: Order received to double production capacity at VGM’s Follum factory30.9.2023 12:00:00 CEST | Press release
On September 30th, 2023, Vow ASA announced that it has received an order from Vow Green Metals AS to enhance the production capacity at their biocarbon production plant in Hønefoss, Norway. This order is an extension of the equipment order received in October 2021, resulting in a new total contract value of NOK 332 million. In addition to some modification on the original equipment order, the expansion will involve the addition of a new process line, effectively doubling the factory's capacity. This will enable the production of up to 20,000 tons of biocarbon annually. The increased capacity is made possible by utilizing self-sufficient renewable gas to power the new reactor technology developed and manufactured by Vow's subsidiary, C. H. Evensen Industriovner AS. This ensures that the expanded capacity remains within the site's power supply limits. Henrik Badin, CEO of Vow ASA, expressed enthusiasm for this solution, emphasizing its ability to enhance efficiency, significantly increas
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote